Hearing loss in a pediatric patient following cisplatin chemotherapy and subsequent exposure to excessive noise

Peleva, Emilia; Aloy, Emilie; Carret, Anne‐Sophie; Daniel, Sam J.

doi:10.1016/j.ijporl.2014.08.039

Cited by 3 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to previous studies considering patients with LOHL, we cannot definitively ascribe that hearing loss is sustained only from the effects of treatment. Other sources, such as harmful levels of noise, could lead to further hearing deterioration in this population . However, quantifying noise exposure was beyond the scope of this investigation.…”

Section: Discussionmentioning

confidence: 98%

Asymmetric sensorineural hearing loss is a risk factor for late‐onset hearing loss in pediatric cancer survivors following cisplatin treatment

Robertson¹,

Hayashi

Camet

et al. 2018

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Background: Ototoxicity is a significant complication of cisplatin treatment. Hearing loss can be symmetric or asymmetric, and may decline after therapy. This study examined the risks of asymmetric and late-onset hearing loss (LOHL) in cisplatin-treated pediatric patients with cancer. Methods:A retrospective review of 993 patients' medical and audiological charts from August 1990 to March 2015 was conducted using stringent criteria to characterize patients with asymmetric hearing loss (AHL) or LOHL. Audiologic data were reviewed for 248 patients that received cisplatin to assess cisplatin-induced sensorineural hearing loss and its associated risk factors.Results: Of the patients evaluable for AHL, 26% exhibited this finding. Of those evaluable for LOHL, 42% of the patients' hearing worsened more than 6 months after therapy completion. Radiation and type of cancer diagnosis were major risk factors for both AHL and LOHL. Furthermore, LOHL was linked to age of diagnosis, noncranial radiation, and longer audiologic follow-up. AHL was strongly associated with LOHL-60% of patients with AHL also had LOHL. Logistic regression analysis revealed that patients with AHL (OR 6.3, 95% CI: 2.2-17.8, P = 0.0005) or those receiving radiation (OR 3.2, 95% CI: 1.2-8.6, P = 0.02) were at greatest risk for LOHL. Conclusion:Children receiving cisplatin therapy are at risk for developing AHL and LOHL. Those that have received radiation and/or with AHL are at increased risk for further hearing decline.Long-term monitoring of these patients is important for early intervention as hearing diminishes. K E Y W O R D Sasymmetric, cisplatin, hearing loss, late-onset, pediatric

show abstract

Section: Discussionmentioning

confidence: 98%